Figure 2.

Pharmacological characterization of NMUR2 agonists NY0116 and NY0128 in calcium and Beta‐arrestin assays. (A) NY0116 and NY0128 activate calcium release in HEK293 cells stably expressing the human NMUR2. (B) Neither agonist increases calcium in wild‐type HEK293 cells that lack expression of NMUR2. [C]) NMS, but not NY0116 or NY0128, dose dependently activates beta‐arrestin recruitment in the Tango assay. (E) 1 nmol/L treatment of cells with the native hormone neuromedin‐S (NMS) activated, whereas 10 μmol/L NY0128 significantly decreased basal NMUR2‐mediated beta‐arrestin activity (*P < 0.05 vs. control, n = 3, one‐way anova). All dose‐response curves are representative plots, performed in quadruplicate, with similar results observed in 3 to 4 independent experiments. NMUR1/2, NMU receptor ½